Astrocyte senescence and SASP in neurodegeneration: tau joins the loop

References

• Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565–581.
   PubMed Web of Science ®Google Scholar
• Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018;128(4):1208–1216.
   PubMed Web of Science ®Google Scholar
• Olivieri F, Prattichizzo F, Grillari J, et al. Cellular senescence and inflammaging in age-related diseases. Mediators Inflamm. 2018;2018:2018.
   Web of Science ®Google Scholar
• Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1(5):a001883.
   PubMed Web of Science ®Google Scholar
• Di Fagagna FDA. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512–522.
   PubMed Web of Science ®Google Scholar
• Young AR, Narita M. SASP reflects senescence. EMBO Rep. 2009;10(3):228–230.
   PubMed Web of Science ®Google Scholar
• Turnquist C, Beck JA, Horikawa I, et al. Radiation-induced astrocyte senescence is rescued by Δ133p53. Neuro Oncol. 2019;21(4):474–485.
   PubMed Web of Science ®Google Scholar
• Turnquist C, Horikawa I, Foran E, et al. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ. 2016;23(9):1515–1528.
   PubMed Web of Science ®Google Scholar
• Nelson G, Wordsworth J, Wang C, et al. A senescent cell bystander effect: senescence‐induced senescence. Aging Cell. 2012;11(2):345–349.
   PubMed Web of Science ®Google Scholar
• Bussian TJ, Aziz A, Meyer CF, et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562(7728):578–582.
   PubMed Web of Science ®Google Scholar
• Dobarro M, Orejana L, Aguirre N, et al. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013;64:137–144.
   PubMed Web of Science ®Google Scholar
• Orejana L, Barros-Miñones L, Jordán J, et al. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol Aging. 2012;33(3):625. e11-625. e20.
   PubMed Web of Science ®Google Scholar
• Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246–1256.
   PubMed Web of Science ®Google Scholar
• Zhang P, Kishimoto Y, Grammatikakis I, et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat Neurosci. 2019;22(5):719–728.
   PubMed Web of Science ®Google Scholar
• Mondal AM, Horikawa I, Pine SR, et al. p53 isoforms regulate aging-and tumor-associated replicative senescence in T lymphocytes. J Clin Invest. 2013;123(12):5247–5257.
   PubMed Web of Science ®Google Scholar
• Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2012;130(8):1715–1725.
   PubMed Web of Science ®Google Scholar
• Roninson IB. Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002;179(1):1–14.
   PubMed Web of Science ®Google Scholar
• Debacq-Chainiaux F, Erusalimsky JD, Campisi J, et al. Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009;4(12):1798.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35.
   PubMed Web of Science ®Google Scholar
• Salminen A, Ojala J, Kaarniranta K, et al. Astrocytes in the aging brain express characteristics of senescence‐associated secretory phenotype. Eur J Neurosci. 2011;34(1):3–11.
   PubMed Web of Science ®Google Scholar
• Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv-Euro J Physiol. 2010;460(2):525–542.
   PubMed Web of Science ®Google Scholar
• Dabir DV, et al. Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J Neurosci. 2006;26(2):644–654.
   PubMed Web of Science ®Google Scholar
• Hunsberger HC, Rudy CC, Batten SR, et al. P301L tau expression affects glutamate release and clearance in the hippocampal trisynaptic pathway. J Neurochem. 2015;132(2):169–182.
   PubMed Web of Science ®Google Scholar
• Limbad C, Oron TR, Alimirah F, et al. Astrocyte senescence promotes glutamate toxicity in cortical neurons. PloS One. 2020;15(1):e0227887.
   PubMed Web of Science ®Google Scholar
• Chinta SJ, Woods G, Demaria M, et al. Cellular senescence is induced by the environmental neurotoxin paraquat and contributes to neuropathology linked to Parkinson’s disease. Cell Rep. 2018;22(4):930–940.
   PubMed Web of Science ®Google Scholar
• Musi N, Valentine JM, Sickora KR, et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell. 2018;17(6):e12840.
   PubMed Web of Science ®Google Scholar
• Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer’s disease. PloS One. 2012;7(9):e45069.
   Web of Science ®Google Scholar
• Hampton DW, Webber DJ, Bilican B, et al. Cell-mediated neuroprotection in a mouse model of human tauopathy. J Neurosci. 2010;30(30):9973–9983.
   PubMed Web of Science ®Google Scholar
• Al-Hilaly YK, Pollack SJ, Vadukul DM, et al. Alzheimer’s disease-like paired helical filament assembly from truncated tau protein is independent of disulfide crosslinking. J Mol Biol. 2017;429(23):3650–3665.
   PubMed Web of Science ®Google Scholar
• Novak M, Kabat J, Wischik C. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. Embo J. 1993;12(1):365–370.
   PubMed Web of Science ®Google Scholar
• Wischik C, Novak M, Thørgersen HC. et al., Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proceedings of the National Academy of Sciences, 1988;85( 12): 4506–4510.
   Google Scholar
• Blennow K, Wallin A, Ågren H, et al. tau protein in cerebrospinal fluid. Molecular and Chemical Neuropathology. 1995;26(3):231–245.
   PubMedGoogle Scholar
• Fá M, Puzzo D, Piacentini R, et al. Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep. 2016;6(1):19393.
   PubMedGoogle Scholar
• Perea JR, Ávila J, Bolós M. Dephosphorylated rather than hyperphosphorylated Tau triggers a pro-inflammatory profile in microglia through the p38 MAPK pathway. Exp Neurol. 2018;310:14–21.
   PubMed Web of Science ®Google Scholar
• Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3(3):205–214.
   PubMed Web of Science ®Google Scholar
• Sohn JJ, Schetter AJ, Yfantis HG, et al. Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS One. 2012;7(9):e44156.
   Web of Science ®Google Scholar
• Jo E-K, Kim JK, Shin D-M, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13(2):148–159.
   PubMed Web of Science ®Google Scholar
• Ising C, Venegas C, Zhang S, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669–673.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284(20):13291–13295.
   PubMed Web of Science ®Google Scholar
• Kovacs GG. Astroglia and tau: new perspectives. Front Aging Neurosci. 2020;12(12).
   Google Scholar
• Gómez-Ramos A, Díaz-Hernández M, Cuadros R, et al. Extracellular tau is toxic to neuronal cells. FEBS Lett. 2006;580(20):4842–4850.
   PubMed Web of Science ®Google Scholar
• Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284(19):12845–12852.
   PubMed Web of Science ®Google Scholar
• Kfoury N, Holmes BB, Jiang H, et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287(23):19440–19451.
   PubMed Web of Science ®Google Scholar
• Stancu I-C, Cremers N, Vanrusselt H, et al. Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. 2019;137(4):599–617.
   PubMed Web of Science ®Google Scholar
• Maeda S, Sahara N, Saito Y, et al. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer’s disease. Neurosci Res. 2006;54(3):197–201.
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58(3):373–379.
   PubMedGoogle Scholar
• Pooler AM, Phillips EC, Lau DHW, et al. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14(4):389–394.
   PubMed Web of Science ®Google Scholar
• Perea JR, Lopez E, Díez-Ballestros, et al. Extracellular monomeric tau is internalized by astrocytes. Front Neurosci. 2019;13:442.
   PubMed Web of Science ®Google Scholar
• Avila J, Jiménez JS, Sayas CL, et al. Tau structures. Front Aging Neurosci. 2016;8:262.
   PubMed Web of Science ®Google Scholar
• Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta Mol Basis Dis. 2005;1739(2–3):280–297.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21(10):428–433.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AW, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547(7662):185–190.
   PubMed Web of Science ®Google Scholar
• Falcon B, Zhang W, Murzin AG, et al. Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature. 2018;561(7721):137–140.
   PubMed Web of Science ®Google Scholar
• Falcon B, Zivanov J, Zhang W, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568(7752):420–423.
   PubMed Web of Science ®Google Scholar
• Narasimhan S, Guo JL, Changolkar L, et al. Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci. 2017;37(47):11406–11423.
   PubMed Web of Science ®Google Scholar
• Sanders DW, Kaufman S, DeVos S, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271–1288.
   PubMed Web of Science ®Google Scholar
• Götz J, Chen F, Barmettler R, et al. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276(1):529–534.
   PubMed Web of Science ®Google Scholar
• Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22(21):9340–9351.
   PubMed Web of Science ®Google Scholar
• Stanford PM, Brooks W, Teber E, et al. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol. 2004;251(9):1098–1104.
   PubMed Web of Science ®Google Scholar
• Skrabana R, Kontsek P, Mederlyova A, et al. Folding of Alzheimer’s core PHF subunit revealed by monoclonal antibody 423. FEBS Lett. 2004;568(1–3):178–182.
   PubMed Web of Science ®Google Scholar
• Zhang W, Falcon B, Murzin AG, et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. Elife. 2019;8:e43584.
   PubMed Web of Science ®Google Scholar
• Al‐Hilaly YK, Foster BE, Biasetti L, et al. Tau (297‐391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer’s disease brain. FEBS Lett. 2019;2020;594(5):944-950.
   PubMed Web of Science ®Google Scholar
• Harrington CR, Storey JMD, Clunas S, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J Biol Chem. 2015;290(17):10862–10875.
   PubMed Web of Science ®Google Scholar
• Morales I, Jiménez JM, Mancilla M, et al. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37(4):849–856.
   PubMed Web of Science ®Google Scholar
• Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337–351.
   PubMed Web of Science ®Google Scholar
• Osorio C, Kanukuntla T, Diaz E, et al. The post-amyloid era in Alzheimer’s disease: trust your gut feeling. Front Aging Neurosci. 2019;11:143.
   PubMed Web of Science ®Google Scholar
• Gerson JE, Castillo-Carranza DL, Kayed R. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. ACS Chem Neurosci. 2014;5(9):752–769.
   PubMed Web of Science ®Google Scholar
• Ward SM, Himmelstein D, Lancia J, et al. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans. 2012;40(4):667–71.
   Google Scholar
• Evans LD, Wassmer T, Fraser G, et al. Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 2018;22(13):3612–3624.
   PubMed Web of Science ®Google Scholar
• Tominaga T, Shimada R, Okada Y, et al. Senescence-associated-β-galactosidase staining following traumatic brain injury in the mouse cerebrum. PloS One. 2019;14(3):e0213673.
   Web of Science ®Google Scholar
• Streit WJ, Braak H, Xue Q-S, et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2009;118(4):475–485.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28(4):202–208.
   PubMed Web of Science ®Google Scholar
• Canudas AM, Gutierrez-Cuesta J, Rodríguez MI, et al. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech Ageing Dev. 2005;126(12):1300–1304.
   PubMed Web of Science ®Google Scholar
• Kawamata T, Akiguchu I, Yagi H, et al. Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory. Exp Gerontol. 1997;32(1–2):161–169.
   PubMed Web of Science ®Google Scholar
• Takeshita S, Hosokawa M, Irino M, et al. Spontaneous age-associated amyloidosis in senescence-accelerated mouse (SAM). Mech Ageing Dev. 1982;20(1):13–23.
   PubMed Web of Science ®Google Scholar
• Coppede F, Migliore L. DNA damage and repair in Alzheimer’s disease. Curr Alzheimer Res. 2009;6(1):36–47.
   PubMed Web of Science ®Google Scholar
• Violet M, Chauderlier A, Delattre L, et al. Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. Neurobiol Dis. 2015;82:540–551.
   PubMed Web of Science ®Google Scholar
• Padmaraju V, Indi SS, Rao KSJ. New evidences on Tau–DNA interactions and relevance to neurodegeneration. Neurochem Int. 2010;57(1):51–57.
   PubMed Web of Science ®Google Scholar
• Cente M, Filipcik P, Pevalova M, et al. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci. 2006;24(4):1085–1090.
   PubMed Web of Science ®Google Scholar
• Frost B, Hemberg M, Lewis J, et al. Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014;17(3):357.
   PubMed Web of Science ®Google Scholar
• Alavi Naini SM, Soussi-Yanicostas N, Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxidative medicine and cellular longevity, 2015. 2015.
   Google Scholar
• Albers DS, Augood SJ, Park LCH, et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem. 2000;74(2):878–881.
   PubMed Web of Science ®Google Scholar
• Castellani R, Smith MA, Richey PL, et al. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res. 1995;696(1–2):268–271.
   PubMed Web of Science ®Google Scholar
• Dumont M, Stack C, Elipenahli C, et al. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. Faseb J. 2011;25(11):4063–4072.
   PubMed Web of Science ®Google Scholar
• Gong L, Gong H, Pan X, et al. p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. Cell Res. 2015;25(3):351–369.
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Shimohama S, Kamoshima W, et al. Changes of p53 in the brains of patients with Alzheimer’s disease. Biochem Biophys Res Commun. 1997;232(2):418–421.
   PubMed Web of Science ®Google Scholar
• Chang JR, Ghafouri M, Mukerjee R, et al. Role of p53 in neurodegenerative diseases. Neurodegen Dis. 2012;9(2):68–80.
   PubMed Web of Science ®Google Scholar
• Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11(9):1135–1142.
   PubMed Web of Science ®Google Scholar
• Horikawa I, Park K-Y, Isogaya K, et al. Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. Cell Death Differ. 2017;24(6):1017–1028.
   PubMed Web of Science ®Google Scholar
• Duncan T, Valenzuela M. Alzheimer’s disease, dementia, and stem cell therapy. Stem Cell Res Ther. 2017;8(1):111.
   PubMedGoogle Scholar
• Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 2015;21(6):394–402.
   PubMed Web of Science ®Google Scholar
• Turnquist C, Harris BT, Harris CC. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neurooncol Adv. 2020;2(1):vdaa057.
   PubMedGoogle Scholar